-+ 0.00%
-+ 0.00%
-+ 0.00%

Calidi Biotherapeutics Presents Data On Approach To Use Of BiTEs In Solid Tumors By Utilizing RedTail Platform At AACR-IO Conference

Benzinga·02/20/2026 13:05:21
Listen to the news

Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California. A link to the poster is available here and on the company's website.

RedTail is Calidi's systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly within the tumor. CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL‑15 superagonist (IL-15 SA), a known T-cell activator, in the TME.